Medicortex started in Q4/2017 a large clinical study in collaboration with two Finnish hospitals. Patients with a suspected TBI, patients with an orthopedic injury, and healthy controls will be recruited in the study. In he first phase, 20 subjects will be recruited in each group after which up to 100 TBI patients will be recruited in the second phase. The study will evaluate, for example, the specificity and sensitivity of the biomarker and its time-related appearance after the injury. The objective is to confirm the clinical relevance of the biomarker.
More information about the study is available at ClinicalTrials.gov/NCT03306563.